Hyperhidrosis: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum Toxins
Open Access
- 22 April 2013
- Vol. 5 (4), 821-840
- https://doi.org/10.3390/toxins5040821
Abstract
Clinical features, anatomy and physiology of hyperhidrosis are presented with a review of the world literature on treatment. Level of drug efficacy is defined according to the guidelines of the American Academy of Neurology. Topical agents (glycopyrrolate and methylsulfate) are evidence level B (probably effective). Oral agents (oxybutynin and methantheline bromide) are also level B. In a total of 831 patients, 1 class I and 2 class II blinded studies showed level B efficacy of OnabotulinumtoxinA (A/Ona), while 1 class I and 1 class II study also demonstrated level B efficacy of AbobotulinumtoxinA (A/Abo) in axillary hyperhidrosis (AH), collectively depicting Level A evidence (established) for botulinumtoxinA (BoNT-A). In a comparator study, A/Ona and A/Inco toxins demonstrated comparable efficacy in AH. For IncobotulinumtoxinA (A/Inco) no placebo controlled studies exist; thus, efficacy is Level C (possibly effective) based solely on the aforementioned class II comparator study. For RimabotulinumtoxinB (B/Rima), one class III study has suggested Level U efficacy (insufficient data). In palmar hyperhidrosis (PH), there are 3 class II studies for A/Ona and 2 for A/Abo (individually and collectively level B for BoNT-A) and no blinded study for A/Inco (level U). For B/Rima the level of evidence is C (possibly effective) based on 1 class II study. Botulinum toxins (BoNT) provide a long lasting effect of 3–9 months after one injection session. Studies on BoNT-A iontophoresis are emerging (2 class II studies; level B); however, data on duration and frequency of application is inconsistent.This publication has 59 references indexed in Scilit:
- Treatment of Palmar Hyperhidrosis With Botulinum Neurotoxin AThe Journal of Hand Surgery, 2013
- Oxybutynin reduces sweating in depressed patients treated with sertraline: a double-blind, placebo-controlled, clinical studyNeuropsychiatric Disease and Treatment, 2012
- Comparing Botox® and Xeomin® for axillar hyperhidrosisJournal of Neural Transmission, 2010
- Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosisAustralasian Journal of Dermatology, 2008
- Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind studyBritish Journal of Dermatology, 2007
- Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: A 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safetyJournal of the American Academy of Dermatology, 2007
- Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosisJournal of the American Academy of Dermatology, 2006
- Randomisierte, plazebokontrollierte klinische Doppelblindstudie zur Wirksamkeit und Verträglichkeit der oralen Therapie mit Methantheliniumbromid (Vagantin®) bei fokaler HyperhidroseJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2004
- Biology of sweat glands and their disorders. II. Disorders of sweat gland functionJournal of the American Academy of Dermatology, 1989
- Biology of sweat glands and their disorders. I. Normal sweat gland functionJournal of the American Academy of Dermatology, 1989